Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG0070 in BCG-unresponsive NMIBC
NCT02365818Phase 2Completed
- Sponsor
- CG Oncology, Inc.
- Start
- Jun 2015
- Primary completion
- Aug 2018
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of cretostimogene grenadenorepvec in non-muscle-invasive bladder cancer (NMIBC), sponsored by CG Oncology, Inc.. Started Jun 2015; status: completed.
02
Drugs
cretostimogene grenadenorepvec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02365818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365818.